Targeting the malaria parasite
Ashley Birkett, director of MVI, highlights efforts to prevent malaria parasite transmission and discusses the value of new tools, such as malaria vaccines.
Malaria vaccine candidate has demonstrated efficacy over 3–4 years of follow-up
Final results from Phase III trial of RTS,S malaria vaccine candidate, including the impact of a booster dose, published today in The Lancet.
Photo credit: James Gathany
Partnering with us
We are pursuing a range of vaccine development approaches with an expanding circle of industry, academic, and government partners.